ThredUp Inc vs Tilray Brands Inc — how do they compare? ThredUp Inc trades at $2.47 (market cap $308.63M), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Tilray Brands Inc is the larger of the two by market cap, and Tilray Brands Inc is more actively traded (9,099,075 versus 3,024,364). Which is the better fit depends on your goals — on Pluang, investors hold ThredUp Inc for 29 Days and Tilray Brands Inc for 31 Days on average.
| TDUP | TLRY | |
|---|---|---|
Market Cap | $308.63M | $530.54M |
Volume | 3,024,364 | 9,099,075 |
Sector | Consumer Cyclical | Health |
52-Week High | $9.41 | $21.00 |
52-Week Low | $2.12 | $3.57 |
Typical Hold Time | 29 Days | 31 Days |
Enterprise Value | $306.81M | $684.46M |
Signals from Pluang's Aura AI — not financial advice
ThredUp (TDUP) trades at $2.455, up 10.59% in the past 24 hours, with a bearish technical signal but strong analyst support. The company reported record Q2 2026 revenue of $90.8 million, up 17% year-over-year, but missed earnings expectations with a net loss. Fundamentals show a high gross margin of 79.52% but negative net income margin and ROE, while cash flow from operations improved to $10.65 million in 2025.
The outlook is mixed: analyst consensus is 57% buy with no sell ratings, but profitability remains a challenge amid promotional headwinds. Risks include ongoing losses, competitive pressures, and a recent stock decline following guidance cuts. Investment opportunity hinges on execution toward profitability despite current bearish technicals.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →